Literature DB >> 9472678

Beta2-glycoprotein I-dependent and -independent anticardiolipin antibody in non-obese diabetic (NOD) mice.

K Anzai1, S Nagafuchi, Y Niho, M Kikuchi, J Ono.   

Abstract

In the present study we investigate whether or not anticardiolipin antibody (aCL) is produced in NOD mice, which is a representative animal model of insulin-dependent diabetes mellitus (IDDM). We found that IgG class aCL appeared in 6.9% of non-diabetic NOD mice at weeks 5-15. The rates increased with age to 31.6% at weeks 16-25 and 71.9% at weeks 26-35. In addition, the titre and incidence of aCL were higher in diabetic mice than in non-diabetic mice. It was also found that aCL in NOD mice involved beta2-glycoprotein I (beta2-GPI)-dependent and -independent aCL, when beta2-GPI was added to the aCL assay system. The IgG subclass of both beta2-GPI-dependent and -independent aCL belonged exclusively to IgG2a. In addition, immunohistochemical studies revealed the predominant accumulation of IgG2a- or IgG3-positive B lymphocytes within insulitis. These results suggest that the autoimmunity in NOD mice may thus be associated with Th1 predominant immunological response. In conclusion, aCL with multiple antigenic specificity were produced in NOD mice along with the development of insulitis and diabetes. NOD mice should thus be added to the list of animal models possessing antiphospholipid antibody.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9472678      PMCID: PMC1904869          DOI: 10.1046/j.1365-2249.1998.00476.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes.

Authors:  J A Shizuru; C Taylor-Edwards; B A Banks; A K Gregory; C G Fathman
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

2.  Autoantibodies in nonobese diabetic mice immunoprecipitate 64,000-Mr islet antigen.

Authors:  M A Atkinson; N K Maclaren
Journal:  Diabetes       Date:  1988-11       Impact factor: 9.461

3.  beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway.

Authors:  I Schousboe
Journal:  Blood       Date:  1985-11       Impact factor: 22.113

4.  beta 2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles.

Authors:  H Wurm
Journal:  Int J Biochem       Date:  1984

5.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

6.  Ontogeny of islet cell antibodies, insulin autoantibodies and insulitis in the non-obese diabetic mouse.

Authors:  S Reddy; N J Bibby; R B Elliott
Journal:  Diabetologia       Date:  1988-05       Impact factor: 10.122

7.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

Authors:  T L Stevens; A Bossie; V M Sanders; R Fernandez-Botran; R L Coffman; T R Mosmann; E S Vitetta
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

8.  Breeding of a non-obese, diabetic strain of mice.

Authors:  S Makino; K Kunimoto; Y Muraoka; Y Mizushima; K Katagiri; Y Tochino
Journal:  Jikken Dobutsu       Date:  1980-01

9.  Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus.

Authors:  T Koike; M Sueishi; H Funaki; H Tomioka; S Yoshida
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

10.  Differential regulation of IgG1 and IgE synthesis by interleukin 4.

Authors:  C M Snapper; F D Finkelman; W E Paul
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

View more
  1 in total

1.  Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus.

Authors:  P Gargiulo; J Goldberg; B Romani; R Schiaffini; P Ciampalini; W P Faulk; J A McIntyre
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.